Analysis of the associations among Helicobacter pylori infection, adiponectin, leptin, and 10-year fracture risk using the fracture risk assessment tool: A cross-sectional community-based study

Li-Wei Chen¹,², Fang-Ping Chen³, Chia-Wen Hsieh², Sheng-Fong Kuo²,⁴, Rong-Nan Chien¹,²*

¹ Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital and University at Keelung, Keelung, Taiwan, ² Community Medicine Research Center, Chang-Gung Memorial Hospital and University at Keelung, Keelung, Taiwan, ³ Department of Obstetrics and Gynecology, Chang-Gung Memorial Hospital at Keelung, Keelung, Taiwan, ⁴ Metabolism and Endocrinology, Chang-Gung Memorial Hospital and University at Keelung, Keelung, Taiwan

* ronald@cgmh.org.tw

Abstract

Helicobacter pylori (H. pylori) infection may induce inflammatory cytokines or adipokines that influence bone turnover and bone fracture risk. This study aimed to evaluate the association among H. pylori infection, adipokines, and 10-year fracture risk using the Fracture Risk Assessment Tool scale. From August 2013 to February 2016, a community-based cohort was surveyed by Keelung Chang-Gung Memorial Hospital. Subjects were included if they were older than 40 years and not pregnant. All participants underwent a standardized questionnaire survey, physical examination, urea breath test, and blood tests. A total of 2,689 participants (1,792 women) were included in this cross-sectional study. In both sexes, participants with a high fracture risk were older and had higher adiponectin values than participants without a high fracture risk (mean age, female: 72.9 ± 5.6 vs. 55.8 ± 7.3 years, P < 0.0001; male: 78.9 ± 4.7 vs. 58.1 ± 8.9 years, P < 0.001) (adiponectin, female: 10.8 ± 6.3 vs. 8.7 ± 5.2 ng/ml, P < 0.001; male: 9.7 ± 6.1 vs. 5.5 ± 3.8 ng/ml, P < 0.001). Adiponectin was correlated with high fracture risk in both sexes, but H. pylori infection and leptin was not. In logistic regression analysis, adiponectin could not predict high fracture risk when adjusting the factor of body mass index (BMI) in men group. In conclusion, H. pylori infection and leptin could not predict 10-year fracture risk in either sex. Adiponectin was correlated with bone fracture risk in both sexes and the correlation might be from the influence of BMI.

Introduction

Osteoporosis is a condition with progressively decreasing bone mineral density (BMD) and increased bone fragility, with increased risk of bone fractures [1,2]. The common sites of
fractures are the spine and hip. Spine and hip fractures caused by osteoporosis are the primary factors responsible for bedbound status and the need for nursing care in the elderly [1,2]. To prevent bone fracture–related comorbidity, it is important to identify patients with underlying diseases or risk factors for osteoporosis and bone fractures. Some well-known risk factors for bone fracture include advancing age, postmenopausal status, low body weight, smoking, excess alcohol consumption, and previous fracture history [3–5]. Some digestive diseases, including inflammatory bowel disease and history of gastrectomy, are also reported to be risk factors for osteoporosis [6–8]. Helicobacter pylori (H. pylori) is a spiral-shaped, Gram-negative bacterium that colonizes the gastric mucosal epithelium. Most patients with H. pylori infection will develop chronic gastritis, which induces inflammatory cytokines, such as interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α). These inflammatory cytokines induce both local and systemic immune responses [9–11]. Adipokines, such as serum adiponectin or leptin, are reportedly associated with the status of H. pylori infection [12–14]. Previous studies have reported that IL-1 and TNF-α trigger bone resorption [15–17]. Adipocytes and osteoblasts have the same mesenchymal stem cell precursors. Hence, adipocytes and osteoblasts share some similar hormones and aspects of cytokine regulation [18, 19]. Past studies have revealed a positive correlation between body fat mass and BMD [18–20]. Osteoporosis develops more often in people with low body weight but less often in obese people [3, 20]. Both adiponectin and leptin have been found to increase osteoblast proliferation and inhibit osteoclast activity [18–21]. Our hypothesis was that H. pylori infection might induce serum inflammatory changes in cytokines (IL-1 and TNF-α) or adipokines (adiponectin and leptin) that influence bone turnover and bone fracture risk. Prior epidemiological studies analyzing the association between H. pylori and osteoporosis showed conflicting results, and most studies had no inflammatory cytokine data [22–29]. If H. pylori infection could be a predictor of bone fracture, giving H. pylori–eradication therapy to prevent bone fracture would be warranted. Although the assay of BMD by dual-energy X-ray absorptiometry is the most common tool used to evaluate bone strength, the use of dual-energy X-ray absorptiometry to predict high risk of bone fracture is limited in mass community screening [30]. The World Health Organization (WHO) has developed a web-based clinical scale, the Fracture Risk Assessment Tool (FRAX), which predicts the 10-year probability of hip or other major osteoporotic fracture [31–33]. The FRAX estimate of risk of fracture is based on the assessment of readily accessible data regarding 10 clinical risk factors for fracture and can be obtained without BMD data [30–36]. Hence, this study aims to evaluate the association between H. pylori infection and 10-year fracture risk using the FRAX scale for 3 communities in northeastern Taiwan. Serum inflammatory cytokines and adipokines were also included in the analyses.

Materials and methods

From August 2013 to February 2016, a community-based survey for metabolic syndrome was performed in 3 districts (Wanli, Ruifang, and Anle) in the northeastern region of Taiwan. A cross-sectional analysis from this cohort was performed. Subjects were included if they were older than 40 years and were not pregnant. All participants completed a demographic survey, physical examination, urea breath test (UBT), and blood tests. A standardized questionnaire was administered to all participants by a trained team of interviewers. The content of the questionnaire included a survey for systemic diseases, such as diabetes mellitus (DM), hypertension, hyperlipidemia, or chronic kidney disease; alcohol consumption and smoking; medication history (oral hypoglycemic agents, vitamin D or calcium supplementation, statins, herbal medicine, hormones or steroid usage, and antibiotics); and family history (malignancy or bone fracture history). The definition of tobacco use was “participants who currently smoke
regardless of the number of cigarette packs.” Excessive alcohol was defined as “men drinking more than 30 g of alcohol and women drinking more than 20 g of alcohol daily.” Secondary osteoporosis was defined as osteoporosis related (or secondary) to diseases such as type 1 (insulin-dependent) diabetes, untreated long-standing hyperthyroidism, hypogonadism, premature menopause (<45 years), chronic malnutrition or malabsorption, and chronic liver disease. These diseases were surveyed by our standard questionnaire. Because this study focused on the association between *H. pylori* infection and bone fracture risk, those who took glucocorticoids, hormone replacement therapy, thyroid/parathyroid drugs, selective estrogen receptor modulators, vitamin D, calcium, bisphosphonates, and proton pump inhibitors were excluded. Those with comorbidity such as history of gastrectomy, inflammatory bowel disease, chronic obstructive pulmonary disease, malignant disease, thyroid or parathyroid disorder, and rheumatoid arthritis were also excluded. The Institutional Review Board of the Chang-Gung Memorial Hospital approved this research (IRB No. 102-2827C, 103-2392C1). Written informed consent was obtained from all subjects before enrollment in this study.

**Body Mass Index (BMI)**

BMI was calculated as weight (kg) divided by height (meters) squared (kg/m²).

**Blood tests**

Blood samples were collected from all participants after overnight fasting and were analyzed within 4 hours after collection for complete blood cell count and biochemistry tests. Adiponectin, leptin and TNF-α levels were determined from additional samples that were stored at -80°C after centrifugation (4°C at 3,000 rpm for 30 min).

**Bone fracture risk assessment**

The FRAX tool without BMD was applied for bone fracture risk assessment (10-year probability of hip or other major osteoporotic fracture). The FRAX is based on the assessment of clinical risk factors, including age, individual and family history of fracture, tobacco use, excessive alcohol consumption, glucocorticoid use, body weight, secondary osteoporosis, and rheumatoid arthritis. There is consensus that people with a 10-year probability of hip fracture ≥3% or a 10-year probability of major osteoporotic fracture ≥20% by FRAX evaluation may be considered to have a high risk of bone fracture and a possible diagnosis of osteoporosis [34]. Local validation revealed good efficiency for bone fracture risk evaluation in postmenopausal women [35].

**Urea breath test**

¹³C-UBT was performed using the Proto Pylori kit (Isodiagnostika, Montreal, Quebec, Canada), with local validation. Results were expressed as delta over baseline (DOB). A local validation test with a DOB cutoff value of 3.5 yielded a sensitivity of 95% and a specificity of 93% [37]. The result of the UBT was recognized as category data (positive or negative) in the regression analysis.

**Adiponectin and leptin**

The assays for adiponectin and leptin employed quantitative sandwich enzyme immunoassay technique and were performed according to the manufacturer’s instructions (Human Total Adiponectin/Acrp30, BioVendor Research and Diagnostic system, Minneapolis, MN, USA; Human Leptin enzyme-linked immunosorbent assay, Clinical Range, BioVendor Laboratory
Medicine, Karasek, Czech Republic). According to the manufacturer’s reference, the normal range of adiponectin value was $\geq 4.6 \mu g/ml$ in women and $\geq 2.04 \mu g/ml$ in men. The normal range of leptin value was $\leq 16.5 ng/ml$ in women and $\leq 7 ng/ml$ in men [38,39].

**Tumor necrosis factor α**

The TNF-α assay used a quantitative sandwich enzyme immunoassay technique and was performed according to the manufacturer’s instructions (Immunite 1000 LKNF1; Siemens Medical Solutions Diagnostics, Lanberis, UK). The normal range of TNF-α value was less than 8.1 pg/ml, according to manufacturer’s reference [40].

**Statistical analysis**

For continuous variables, values were expressed as means and standard deviations (SD). The chi-square test or Fisher’s exact test were applied for categorical data analysis. All statistical tests were 2-tailed, and $P < 0.05$ indicates a statistically significant difference. By maximizing Youden’s index and receiver operating characteristic (ROC) curve analysis, an optimal cutoff point of age to predict high 10-year fracture risk could be evaluated. Using the continuous variable of 10-year hip fracture probability (%) by FRAX assessment and age period, a lifetime bone fracture probability curve was created by dividing the participants into those with and without *H. pylori* infection. The associations among *H. pylori* infection (evaluated by UBT), TNF-α, adiponectin, leptin, and bone fracture risk (evaluated by FRAX scale) were evaluated using Pearson’s or Spearman’s correlation coefficients. Phi coefficient was applied for binary data, such as *H. pylori* infection; Spearman’s coefficient rho was applied for a nonparametric measure of rank correlation, such as bone fracture risk; Pearson’s correlation was applied for continuous data, such as high-sensitivity C-reactive protein, TNF-α, adiponectin, and leptin. Because people with high bone fracture risk by FRAX evaluation were older and had lower BMI, multivariate logistic regression analysis was performed after adjusting for potential confounders of age and BMI. Other risk factors of smoking and excess alcohol consumption were also adjusted for bone fracture assessment by logistic regression analysis. SPSS for Windows software (Version 16.0, SPSS Inc., Chicago, IL, USA) was used for analysis.

**Results**

Initially, 2,760 participants were enrolled. Finally, a total of 2,689 participants (897 men and 1,792 women) were included in this study (Fig 1, flowchart). The demographic data list was divided into 2 groups according to sex (Table 1). The percentage of individuals with high fracture risk was greater in women compared to men (324/1,792, 18.1%, vs. 93/897, 10.4%, $P < 0.001$). According to the questionnaire, 188 women (10.5%, 188/1,792) and 92 men (10.3%, 92/897) reported gastrointestinal symptoms. The usual symptoms were epigastric pain (82%), abdominal fullness (34%), and gastroesophageal reflux disease (18%). There was no statistical difference in the distribution of gastrointestinal symptoms between participants with and without high fracture risk in both sexes.

In women, participants with a high 10-year fracture risk were older and had higher adiponectin values than participants with a low 10-year fracture risk (mean age, 72.9 ± 5.6 vs. 55.8 ± 7.3 years, $P < 0.001$; adiponectin, 10.8 ± 6.3 vs. 8.7 ± 5.2 ng/ml, $P < 0.001$). However, the distribution of *H. pylori* infection (UBT-positivity) was not significantly different between the high and low 10-year fracture risk participants (54.6% vs. 53.4%, $P = 0.689$).

In men, the participants with a high 10-year fracture risk were also older and higher adiponectin values, than participants without a high 10-year fracture risk (mean age, 78.9 ± 4.7 vs. 58.1 ± 8.9 years, $P < 0.001$; adiponectin, 9.7 ± 6.1 vs. 5.5 ± 3.8 ng/ml, $P < 0.001$). The
There were five participants with chronic obstructive pulmonary disease (COPD) and two participants with rheumatoid arthritis (RA). Three participants with COPD and 1 with rheumatoid arthritis who took steroid for disease control. Two participants with COPD took PPI for chronic cough possibly related to gastroesophageal reflux disease (GERD). Another one patient with RA did not take steroid.

Fig 1. A flow diagram of participants. There were five participants with chronic obstructive pulmonary disease (COPD) and two participants with rheumatoid arthritis (RA). Three participants with COPD and 1 with rheumatoid arthritis who took steroid for disease control. Two participants with COPD took PPI for chronic cough possibly related to gastroesophageal reflux disease (GERD). Another one patient with RA did not take steroid.

https://doi.org/10.1371/journal.pone.0175365.g001
distribution of *H. pylori* infection (UBT-positivity) was also not significantly different between the high and low 10-year fracture risk participants (58.1% vs. 54.7%, *P* = 0.540).

The mean serum calcium value was lower in male participants with high fracture risk than in those without high risk (9.2 ± 0.3 vs. 9.4 ± 0.3, *P* = 0.001). However, there was no significant difference in mean serum calcium value between female participants with high fracture risk and those without high risk. Among participants with and without *H. pylori* infection, the mean serum calcium values showed no significant difference.

By maximizing Youden's index and ROC curve analysis, the optimal cutoff point of age to predict high 10-year fracture risk was 65.5 years in all participants (sensitivity, 95.0%; specificity, 87.3%). Using the 10-year hip fracture probability (%) by FRAX assessment and age period, Fig 2 revealed a lifetime bone fracture probability curve by dividing the participants into those with and without *H. pylori* infection. There was no significant difference of hip fracture probability in every age period between participants with and without *H. pylori* infection. In both sexes, a rapidly increasing fracture risk by hip fracture probability >3% was found in participants older than 65 years.

Bivariate correlations and multivariate logistic regression analysis between the 10-year fracture risk and risk factors, such as age, BMI, smoking, excess alcohol consumption, *H. pylori* infection, and adiponectin, leptin, TNF-α, and high-sensitivity C-reactive protein levels, are shown in Table 2 (correlation analysis) and Table 3 (logistic regression analysis). *H. pylori* infection and leptin were not correlated with bone fracture risk in both sexes. Adiponectin values were positively correlated with fracture risk in both sexes (*P* < 0.05). However, when adjusting the confounding factor of BMI, there was no statistical difference of adiponectin value for the odds ratio of high fracture risk in men group by multivariate logistic regression. There may be an existence of co-linearity between adiponectin and BMI in this regression analysis.

---

### Table 1. Demography and characteristics of participants with and without high risk of 10-year bone fracture probability by sexes.

|                          | Male            | Female          |
|--------------------------|-----------------|-----------------|
|                          | High risk for fracture (%) | High risk for fracture (%) | *P* value<sup>a</sup> | High risk for fracture (%) | High risk for fracture (%) | *P* value<sup>a</sup> |
| Number (%)<sup>b</sup>   | 804 (89.6)      | 93 (10.4)       | 1,468 (81.9) | 324 (18.1) | <0.001 |
| Major osteoporotic fracture (%)<sup>c</sup> | 4.1 ± 1.9      | 10.1 ± 4.0      | <0.001 | 4.9 ± 2.3     | 13.7 ± 3.1      | <0.001 |
| Hip fracture (%)<sup>c</sup> | 0.8 ± 0.8      | 4.9 ± 2.2      | <0.001 | 1.0 ± 0.8     | 5.9 ± 2.3      | <0.001 |
| Mean age (years)         | 58.1 ± 8.9      | 78.9 ± 4.7      | <0.001 | 55.8 ± 7.3     | 72.9 ± 5.6      | <0.001 |
| BMI                      | 25.6 ± 3.5      | 23.7 ± 2.8      | <0.001 | 24.4 ± 3.7     | 24.1 ± 3.6      | 0.092 |
| Alcohol (%)              | 102 (12.7)      | 3 (3.2)         | 0.007 | 35 (2.4)       | 0 (0)          | 0.005 |
| Smoking (%)              | 405 (50.4)      | 46 (49.5)       | 0.868 | 103 (7.0)      | 11 (3.4)       | 0.016 |
| UBT (*H. pylori*) (%)     | 440 (54.7)      | 54 (58.1)       | 0.540 | 784 (53.4)     | 177 (54.6)     | 0.689 |
| HS-CRP                   | 2.3 ± 6.2       | 3.7 ± 11.9      | 0.042 | 2.0 ± 4.5     | 2.4 ± 8.0      | 0.299 |
| TNF-α                    | 8.2 ± 5.8       | 8.7 ± 4.3       | 0.231 | 7.4 ± 4.6     | 8.8 ± 9.1      | <0.001 |
| Adiponectin              | 5.5 ± 3.8       | 9.7 ± 6.1       | <0.001 | 8.7 ± 5.2     | 10.8 ± 6.3     | <0.001 |
| Leptin                   | 8.1 ± 6.5       | 7.7 ± 5.8       | 0.699 | 15.3 ± 8.7    | 14.7 ± 9.2     | 0.773 |
| Calcium                  | 9.4 ± 0.3       | 9.2 ± 0.3       | <0.001 | 9.4 ± 0.3     | 9.4 ± 0.3      | 0.925 |

<sup>a</sup> *P* value: categorical data (*H. pylori* %), chi-square test; continuous data, t test.

<sup>b</sup> Comparison of the distribution percentage of high fracture risk between men and women.

<sup>c</sup> The 10-year bone fracture probability using the Fracture Risk Assessment Tool. BMI = body mass index (kg/m²); HS-CRP = high-sensitivity C-reactive protein; TNF-α = tumor necrosis factor alpha; UBT (*H. pylori*) = urea breath test.

https://doi.org/10.1371/journal.pone.0175365.t001
Factors correlated with bone fracture risk were entering the logistic regression analysis. These factors were age, BMI, adiponectin and alcohol for men group and age, smoking, adiponectin and TNF-α for women group. Although the factor of alcohol was correlated with bone fracture risk in women group, alcohol was not entering the regression analysis in women group. The reason was no women in high fracture risk reported to drink excess alcohol.

Table 2. Bivariate correlation between factors and high fracture risk.

| Factor     | Men          | Women          |
|------------|--------------|----------------|
| Age        | 0.598*       | 0.684*         |
| BMI        | -0.163*      | -0.040         |
| Alcohol    | -0.090*      | -0.066*        |
| Smoking    | -0.006       | -0.057*        |
| H. pylori  | 0.020        | 0.009          |
| HS-CRP     | 0.012        | 0.034          |
| TNF-α      | 0.028        | 0.096*         |
| Adiponectin| 0.298*       | 0.148*         |
| Leptin     | -0.016       | -0.025         |

* Phi coefficient analysis for binary category data (H. pylori) and Spearman's coefficient rho for rank correlation (high bone fracture risk) and Pearson's correlation coefficient for continuous data (HS-CRP, TNF-α, adiponectin, leptin). BMI = body mass index; HS-CRP = high-sensitivity C-reactive protein; TNF-α = tumor necrosis factor alpha;

https://doi.org/10.1371/journal.pone.0175365.t002
(N = 0). It may be not necessary to enter alcohol into adjustment for the regression analysis in women group. Hence, according to logistic regression analysis to estimate odds for high 10-year fracture risk with adjustments for age, smoking and excess alcohol consumption, adiponectin could predict bone fracture risk in both sexes. However, adiponectin losses the predictor role for bone fracture risk when entering the factor of BMI into adjustment in men group. An existence of co-linearity between adiponectin and BMI was found in this regression analysis for bone fracture risk.

Fig 3 shows the mean adiponectin and leptin values in individuals with or without H. pylori infection by age stratification. The mean adiponectin values were increased in older participants. The mean adiponectin and leptin values were higher in women than in men. In every age group, there was no significant difference in mean adiponectin and leptin values between participants with and without H. pylori infection. The correlation and regression analysis revealed no association between adiponectin/leptin values and H. pylori infection in this study.

Discussions

Past studies about the association between H. pylori infection and osteoporosis or fracture risk are shown in Table 4. Four studies reported a positive association between H. pylori infection and osteoporosis [22,27–29]. Figura et al. [22] reported that male patients infected by CagA protein–producing H. pylori strains had higher values of a urinary bone fracture biomarker. Two hospital-based studies from Japan by Asaoka et al. [27,29] and 1 from Taiwan by Lin et al. [28] reported an association between H. pylori infection and osteoporosis. Subjects in a hospital-based group may include symptomatic patients with more severe inflammatory conditions, such as erosive gastritis, peptic ulcers, and gastric mucosal atrophy [27–29]. Although there was no detailed information about the serum calcium, inflammatory cytokine, or estrogen level in these 3 studies, the authors tried to explain the association with H. pylori infection-related diseases and osteoporosis based on 3 reasons. The first reason was that gastric mucosal atrophy related to H. pylori infection might induce malabsorption of calcium, which plays a crucial role in mineral homeostasis and bone metabolism [25]. The second reason was that systemic inflammatory cytokines related to H. pylori infection interfered with the differentiation of osteoclasts, which are related to bone destruction [11,15]. The third reason was that patients with CagA-expressing H. pylori strains had a lower serum estrogen level than those infected by non-CagA-expressing strains and normal controls of both sexes [22]. Estrogen deficiency

| Table 3. Multivariate logistic regression between factors and high fracture risk. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Factor          | Multivariate regression |                |
|                 | Model 1 (OR (95% CI)) | Model 2 (OR (95% CI)) | Model 3 (OR (95% CI)) |
|                 | Age  | 2.131 (1.701–2.670) | 2.131 (1.701–2.670) | 2.131 (1.701–2.670) |
| BMI             | 0.735 (0.598–0.904)  | 0.735 (0.598–0.904)  | 0.735 (0.598–0.904)  |
| Alcohol         | 0.247 (0.075–0.809)  | 0.247 (0.075–0.809)  | 0.247 (0.075–0.809)  |
| Adiponectin     | 1.185 (1.133–1.240)  | 1.185 (1.133–1.240)  | 1.185 (1.133–1.240)  |
| Smoking         | 0.549 (0.279–1.079)  | 0.549 (0.279–1.079)  | 0.549 (0.279–1.079)  |
| TNF-α           | 1.040 (1.008–1.074)  | 1.040 (1.008–1.074)  | 1.040 (1.008–1.074)  |
| Adiponectin     | 1.064 (1.040–1.089)  | 1.064 (1.040–1.089)  | 1.064 (1.040–1.089)  |

OR = odd ratio; 95% CI = 95% confidence interval.

https://doi.org/10.1371/journal.pone.0175365.t003
Fig 3. Mean values of adiponectin and leptin in participants with or without *H. pylori* infection. The numbers on the X-axis indicate the age interval (every 5 years) from 40 to 90 years old. The numbers on Y-axis axis indicate the serum concentrations of adiponectin (μg/ml) and leptin (ng/ml). The mean serum adiponectin values increased with increased ages of participants. The mean adiponectin and leptin values were higher in women than in men. There was no significant difference in mean adiponectin and leptin values between participants with and without *H. pylori* infection in any age period.

https://doi.org/10.1371/journal.pone.0175365.g003

Table 4. Recent studies about the association between *H. pylori* and Osteoporosis/Bone fracture risk.

| Year/nation/first author | Sex/age (years) (number)a | H. pylori detection | Bone fracture risk survey | Association | Ref |
|--------------------------|--------------------------|---------------------|---------------------------|-------------|-----|
| 2005/Italy/Figura        | Male/65 (80/160)         | Serum antibody      | Urinary biomarker         | Positive in CagA (+) strain | [22] |
| 2007/Brazil/Kakebasi     | Female/61.7 (50/0)       | C13 UBT/RUT/ histology | DEXA for osteoporosis     | No association   | [23] |
| 2007/Turkey/Ozdem        | Both/11.8 (41/20)        | RUT/histology       | Biochemical markers       | No association   | [24] |
| 2009/Brazil/Kakebasi     | Female/63.7 (34/0)       | Histology/UBT       | DEXA for osteoporosis     | No association   | [25] |
| 2011/Turkey/Akkaya       | Female/65.3 (58/47)      | Serum antibody      | DEXA for osteoporosis     | No association   | [26] |
| 2014/Japan/Asaoka        | Both/63.1 (41/159)       | C13 UBT/serum antibody| DEXA for osteoporosis     | Positive        | [27] |
| 2015/Taiwan/Lin          | Female/77.3 (101/264)    | Histology/RUT       | DEXA for osteoporosis     | Positive in patients with upper GI symptoms | [28] |
| 2015/Japan/Asaoka        | Both/63.2 (43/212)       | C13 UBT/serum antibody| DEXA for osteoporosis     | Positive        | [29] |

a Number, potential risk for bone fracture patients/control.
DEXA = dual-energy X-ray absorption; RUT = rapid urease test; serum antibody = serum anti-*H. pylori* antibody; UBT = urea breath test.

https://doi.org/10.1371/journal.pone.0175365.t004
related to CagA-positive *H. pylori* infection was the reason for increasing bone resorption and fracture risk [22,41,42]. In our study, the majority of subjects had no symptom of gastrointestinal disease. Our study revealed no significant differences in *H. pylori* infection distribution between people with and without a high risk of fracture in either sex. Moreover, the mean serum calcium value was not significantly different between those with and without *H. pylori* infection. We could not confirm if the positive association between *H. pylori* infection and osteoporosis would only occur in symptomatic patients because most subjects in our study were asymptomatic. Further studies to elucidate the association between *H. pylori* infection and bone fracture risk are warrant by including more patients with *H. pylori* related diseases, such as atrophic gastritis or increasing serum inflammatory cytokines.

In our study, adiponectin levels were highest in older (age, older than 60 years) postmenopausal women, followed by premenopausal women, and lowest in men. This finding was similar to that of a report by Napoli et al. [26], in which serum adiponectin level was significantly lower in elderly men than in elderly women. Past studies revealed a reverse association between sex hormones (estrogen, testosterone) and adiponectin. Both estrogen and testosterone have a suppressive effect on serum adiponectin [43]. In postmenopausal status, women have decreasing estrogen but increasing adiponectin concentration. Because estrogens can inhibit osteoclast-mediated bone resorption, the positive correlation between osteoporosis and serum adiponectin values could partially be explained by the decreasing estrogen level.

The current study revealed a positive correlation between adiponectin values and 10-year bone fracture probability. This finding was similar to that of some previous studies in which an inverse association between adiponectin and BMD was reported [18, 21]. However, on further regression analysis by adjusting the factors of age and BMI, we could not find associations among adiponectin, leptin, and fracture risk. This revealed a probable confounding effect of body fat and age on the analysis of adiponectin and leptin values. Moreover, recent studies focused on the increase in bone marrow adiposity in osteoporotic patients [44]. Hence, it may be that adipokine level in bone marrow supernatant fluids but not serum total adipokine concentration can discriminate between healthy and osteoporotic status. Further study is needed to determine the importance of adipokine levels in bone marrow fluid to the prediction of osteoporosis outcomes.

Advancing age is an important factor for osteoporosis and bone fracture. In the current study, an age cutoff point of 65.5 years for predicting high bone fracture risk by ROC curve analysis was compatible with the results of previous studies that elderly people (older than 65 years) have highly increased bone fracture risk [4,5,32].

There are some limitations. First, this was a community-based study of more than 2,000 individuals, but the results of BMD were not available for all participants. Hence, FRAX without BMD was applied for the 10-year fracture probability survey. From a Korean study, the FRAX model without BMD appears to show a slightly lower fracture probability compared to that calculated with BMD, especially in younger participants [34]. The current study aimed to evaluate the predictive roles of *H. pylori* infection and adipokines for fracture risk. The mean age of participants was about 60 years (not young participants). The application of FRAX without BMD for bone fracture survey is acceptable in this study. The other concern was the short period of surveillance for 10-year bone fracture risk in this study. The outcome of bone fracture did not happen and the fracture risk assessment was uncertain. Second, endoscopy or serum pepsinogen levels were not performed for *H. pylori*-related atrophic gastritis evaluation in this study. Because the use of endoscopy is limited in a community survey, no data about gastric mucosal atrophy was available in our study. According to the questionnaire survey, the majority of our participants had no gastrointestinal symptoms. The mean serum calcium values in participants with and without *H. pylori* infection showed no significant difference in
this study. Whether patients with atrophic gastric mucosa have lower serum calcium levels could not be elucidated in the current study. The last limitation was selection bias. Our study originated from community-based health checkup data. The participants may consist of older adults with underlying diseases and desire for medical examinations. As with the other cross-sectional study designs, unmeasured confounding factors or covariates might exist in this study. In the other way, alcohol consumption survey was performed by questionnaire and no women with high fracture risk reported to drink excess alcohol. People who drank excess alcohol might claim no alcohol consumption in questionnaire. It may be a drawback by questionnaire survey method.

There was no conclusive association among *H. pylori* infection, serum leptin values, and bone fracture risk in this study. Although adiponectin was positively correlated with high fracture risk in both sexes, the significant difference disappeared in multivariate analysis by adjusting for the factor of BMI in men group. There may be an existence of co-linearity between adiponectin and BMI in this regression analysis.

**Supporting information**

S1 Table. STROBE checklist. STROBE checklist for the cross-sectional observational study. (DOC)

**Author Contributions**

**Conceptualization:** LWC FPC SFK RNC.

**Data curation:** LWC CWH.

**Formal analysis:** LWC CWH.

**Funding acquisition:** LWC.

**Investigation:** LWC CWH RNC.

**Methodology:** LWC FPC RNC.

**Project administration:** LWC RNC.

**Resources:** LWC CWH.

**Supervision:** RNC.

**Validation:** LWC CWH.

**Visualization:** LWC RNC.

**Writing – original draft:** LWC.

**Writing – review & editing:** LWC RNC.

**References**

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285:785e96.
2. Suzuki T, Yoshida H. Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporos Int. 2010; 21:71–9. https://doi.org/10.1007/s00198-009-0970-5 PMID: 19499274
3. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005; 16:581–9. https://doi.org/10.1007/s00198-004-1780-5 PMID: 15616758
4. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA. 2007; 298:2389–98. https://doi.org/10.1001/jama.298.20.2389 PMID: 18042916

5. Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med. 2008; 148:685–701. PMID: 18458282

6. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003; 124:795–841. https://doi.org/10.1016/S0016-5085(03)00888-9 PMID: 12612917

7. Schulte CM. Review article: bone disease in inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20(Suppl 4):43–9.

8. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Osteoporosis after gastrectomy: bone mineral density of lumbar spine assessed by dual-energy X-ray absorptiometry. Calcif Tissue Int. 2000; 66:119–22. PMID: 10652959

9. Crabtree JE. Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol Ther. 1996; 10(Suppl 1):29–37.

10. Thalmaier U, Lehnhart P, Pfeffer K, Stolte M, Lehn N, Hoek FJ, van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol. 1994; 29:425–9. PMID: 8036458

11. Breidert M, Miehlke S, Glasow A, Orban Z, Stolte M, Ehninger G, et al. Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori–associated gastritis. Scand J Gastroenterol. 1999; 34:954–61. PMID: 10563663

12. Azuma T, Suto H, Ito Y, Ohtani M, Dojo M, Kuriyama M, et al. Gastric leptin and Helicobacter pylori infection. Gut. 2001; 49:324–9. https://doi.org/10.1136/gut.49.3.324 PMID: 11511551

13. Polyzos SA, Kountouras J, Papaioannou A, Patsioura K, Katsiki E, Zafeiriadou E, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013; 62:121–6. https://doi.org/10.1016/j.metabol.2012.06.007 PMID: 22841522

14. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis—the second decade. Endocrinology. 1998; 139(6):2659–61.

15. Odabas E, Ozata M, Turan M, Bingöl M, Yünen A, Cakır B, et al. Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol. 2000; 142:170–3. PMID: 10664526

16. Liu K, Liu P, Liu R, Wu X, Cai M. Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. Clin Chim Acta. 2015; 444:260–3. https://doi.org/10.1016/j.cca.2015.02.040 PMID: 25748037

17. Biver E, Salliot C, Combescure C, Gosses L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:2703–13. https://doi.org/10.1210/jc.2011-0047 PMID: 21778223

18. Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, Mohiti A. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. 2014; 32:400–4. https://doi.org/10.1007/s00774-013-0511-4 PMID: 24052207

19. Lim S, Joung H, Shin CS, Lee HK, Kim KS, Shin EK, et al. Body composition changes with age have gender-specific impacts on bone mineral density. Bone. 2004; 35:792–8. https://doi.org/10.1016/j.bone.2004.05.016 PMID: 15336618

20. Napoli N, Pedone C, Pozzilli P, Lauretani F, Ferrucci L, Incalzi RA. Adiponectin and bone mass density: the In CHIANTI study. Bone. 2010; 47:1001–5. https://doi.org/10.1016/j.bone.2010.08.010 PMID: 20804877

21. Figura N, Gennari L, Merlotti D, Lenzi C, Campagna S, Franci B, et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig Dis Sci. 2005; 50:847–52. PMID: 15906756

22. Kakehashi AM, Mendes CM, Coelho LG, Castro LP, Barbosa AJ. The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density. Arq Gastroenterol. 2007; 44:266–70. PMID: 18060283

23. Ozdem S, Akcam M, Yilmaz A, Gultekin M, Aertan R. Biochemical markers of bone metabolism in children with Helicobacter pylori infection. Dig Dis Sci. 2007; 52:967–72. https://doi.org/10.1007/s10620-006-9292-0 PMID: 17318389
25. Kakehasi AM, Rodrigues CB, Carvalho AV, Barbosa AJ. Chronic gastritis and bone mineral density in women. Dig Dis Sci. 2009; 54:819–24. [https://doi.org/10.1007/s10620-008-0417-5 PMID: 18685818]

26. Akkaya N, Akkaya S, Polat Y, Turk M, Turk T, Ergur S, et al. Helicobacter pylori seropositivity in patients with postmenopausal osteoporosis. J Phys Ther Sci. 2011; 23:61–4.

27. Asaoka D, Nagahara A, Hojo M, Sasaki H, Shimada Y, Yoshizawa T, et al. The relationship between H. pylori infection and osteoporosis in Japan. Gastroenterol Res Pract. 2014:340765. [https://doi.org/10.1155/2014/340765 PMID: 25024699]

28. Lin SC, Koo M, Tsai KW. Association between Helicobacter pylori infection and risk of osteoporosis in elderly Taiwanese women with upper gastrointestinal diseases: a retrospective patient record review. Gastroenterol Res Pract. 2014; 2014:814756. [https://doi.org/10.1155/2014/814756 PMID: 24959176]

29. Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, et al. Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori? Ther Clin Risk Manag. 2015; 11:381–91. [https://doi.org/10.2147/TCRM.S80647 PMID: 25834453]

30. Siris ES, Adler R, Bilezikian J, Bolognesi M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014; 25:1439–43. [https://doi.org/10.1007/s00198-014-2655-z PMID: 24577348]

31. Mechanick JI, Camacho PM, Cobin RH, Garber AJ, Garber JR, Gharib H, et al. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines–2010 update. Endocr Pract. 2010; 16:270–83. [https://doi.org/10.4158/EP.16.2.270 PMID: 20350905]

32. Kanis JA, Oden A, Johansson O, Johansson H, Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007; 18:1033–46. [https://doi.org/10.1007/s00198-007-0343-y PMID: 17323110]

33. Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012; 23:75–85. [https://doi.org/10.1007/s00198-011-1747-2 PMID: 21850546]

34. Kima JW, Koh JM, Park JH, Chang JS. Validation of FRAX without BMD: an age-related analysis of the Fifth Korea National Health and Nutrition Examination Survey (KNHANES V-1, 2010). Bone. 2015; 75:27–31. [https://doi.org/10.1016/j.bone.2015.02.013 PMID: 25697083]

35. Chao AS, Chen FP, Lin YC, Huang TS, Fan CM, Yu YW. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women. Taiwan J Obstet Gynecol. 2015; 54:722e725.

36. Siris ES, Adler R, Bilezikian J, Bolognesi M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014; 25:1439–43. [https://doi.org/10.1007/s00198-014-2655-z PMID: 24577348]

37. Chen LW, Chien RN, Fang KM, Yen CL, Chang JJ, Lee TS, et al. A comparative study on Helicobacter pylori infection in peptic ulcer disease patients with or without previous eradication therapy. Hepatogastroenterology. 2007; 54:2209–11. PMID: 18265634

38. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schultheiss T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003; 278:9073–85. [https://doi.org/10.1074/jbc.M207198200 PMID: 12496257]

39. Dubuc GR, Phinney SD, Stern JS, Havel PJ. Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women. Metabolism. 1998; 47:429–34. PMID: 9550541

40. Teppo AM, Maury CP. Radioimmunoassay of tumor necrosis factor in serum. Clin Chem. 1987; 33:2024–7. PMID: 3677374

41. Pacifici R. Cytokines, estrogen, and postmenopausal osteoporosis—the second decade. Endocrinology. 1998; 139:2659–61.

42. Khosla S, Melton LJ 3rd, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002; 87:1443–50. [https://doi.org/10.1210/jcem.87.4.8417 PMID: 11932262]

43. Lubkowska A, Dobek A, Mieszkowski J, Garczynski W, Chlubek D. Adiponectin as a biomarker of osteoporosis in postmenopausal women: controversies. Dis Markers. 2014; 2014:975178. [https://doi.org/10.1155/2014/975178 PMID: 24591772]

44. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2:35–43. [https://doi.org/10.1038/ncprheum0070 PMID: 16932650]